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Excitement and controversy followed the discovery that a frequently occurring single nucleotide polymor-
phism in noncoding DNA affects cancer susceptibility. In this issue of Cancer Cell, Post et al. (2010) report
using a mouse model to demonstrate directly that this subtle genetic variation significantly attenuates the
p53 pathway and accelerates tumor formation.The human genome shows a remarkable
degree of variation, as revealed by whole-
genome sequencing and high-throughput
array-based methods. Polymorphisms
include copy number variations, inver-
sions, rearrangements, and single nucleo-
tide polymorphisms (SNPs). SNPs have
been particularly useful as markers of
susceptibility to disease conditions such
as cancer, diabetes, neurodegeneration,
heart failure, and infection. As most
SNPs are found in noncoding DNA or are
synonymous (i.e., do not change encoded
amino acids), they are usually thought to
be merely genetic markers of regions of
interest. However, in this issue of Cancer
Cell, Post and colleagues provide in vivo
and mechanistic evidence that a SNP in
the promoter of the MDM2 gene directly
affects the p53 pathway of tumor
suppression.
Either highly penetrant gene mutations
or weaker genetic variants may confer
increased cancer risk. For example,
familial breast cancer is associated with
mutations in the BRCA1 and BRCA2
genes (Balmain et al., 2003). Germline
mutations of TP53 (p53) cause Li-Frau-
meni Syndrome (LFS), which is character-
ized by predisposition to various malig-
nancies that usually arise at a relatively
young age and the development of mul-
tiple primary tumors. p53 is normally
induced in response to stress, resulting
in gene transcription that culminates in
cell-cycle arrest, senescence, or apo-
ptosis, which in turn eliminates damaged
cells. Mutation of p53 or the dysregulation
of p53 pathway components inactivate
this protective mechanism and can lead
to malignancy. Somatic mutations in p53
are the most common specific genetic
alteration in human cancer; therefore,
one might anticipate that even subtle
genetic variations that alter the functionof p53 regulators would also affect
the p53 pathway and, thus, tumor devel-
opment.
Indeed, a SNP was identified in the
promoter of the MDM2 gene that affects
cancer incidence in humans (Bond et al.,
2004). MDM2 encodes a ubiquitin ligase
that binds and ubiquitinates p53, target-
ing it for degradation by the proteasome.
MDM2 is a major negative regulator of
p53, because the embryonic lethality of
Mdm2 null mice is caused by the uncon-
trolled activity of p53 and rescued by its
deletion (Lozano, 2010). Furthermore,
MDM2 is required to keep the sponta-
neous activity of p53 constantly in check,
otherwise rampant apoptosis results in
tissue damage and eventual death (Ring-
shausen et al., 2006).
The T-to-G SNP in the second promoter
of the humanMDM2 gene has been asso-
ciated with increased tumor susceptibility
in humans. The presence of the G nucleo-
tide at this position facilitates binding of
the transcription factor Sp1, leading to
increased MDM2 transcription. Elevated
levels of MDM2 suppress activation of
the p53 pathway, including p53-depen-
dent apoptosis (Figure 1). These findings
are important because 40% of healthy
people are heterozygous for the
MDM2SNP309G allele (i.e., T/G) and 12%
are homozygous (i.e., G/G) (Bond et al.,
2004). The biochemical data predict
that these people should be more prone
to cancer because their ability to acti-
vate the p53 pathway in response to
stress is suppressed. Indeed, analysis
of LFS patients show that 75% of
MDM2SNP309G/G individuals develop mul-
tiple tumors, in contrast to the
59% of MDM2SNP309G/T and 18% of
MDM2SNP309T/T individuals who do so
(Bond et al., 2004). However, various clin-
ical studies investigating the associationCancer Cell 18, Seof the MDM2SNP309G allele with cancer
susceptibility have yielded conflicting
results.
To address this controversy, Post
and colleagues replaced the mouse
Mdm2 alleles with humanized ones,
Mdm2SNP309G and Mdm2SNP309T. They
also study this SNP in the context of a
mouse model for LFS, in which the mice
carry a knockin p53 mutation (p53515A)
and, thus, express the mutant protein
p53R172H (Lang et al., 2004). This study
confirms that the Mdm2SNP309G allele
has the same effect in mice that it does
in humans on Sp1 binding, Mdm2 tran-
scription, and p53 pathway activation.
Mdm2SNP309G/G mice develop tumors
earlier and have shorter lifespans than
Mdm2SNP309T/T mice. The same result
was seen in Mdm2SNP309G/G p53515A/+
and Mdm2SNP309T/T p53515A/+ mice.
In fact, 26% of the Mdm2SNP309G/G
p53515A/+ mice developed multiple
primary tumors, whereas only 5% of the
Mdm2SNP309T/T p53515A/+ mice did so,
mirroring the increased tumor burden of
LFS patients with theMDM2SNP309G allele
(Bond et al., 2004). Given that these mice
have identical genetic backgrounds and
are kept under identical environmental
conditions, these observations prove
conclusively that the MDM2SNP309G allele
does indeed increase tumor suscepti-
bility.
Although MDM2SNP309G only subtly
modulates the p53 pathway, its biological
consequences are profound, which is
consistent with previous genetic and
biochemical studies demonstrating the
important role of gene dosage in the p53
pathway. For example, mice with an
Mdm2 hypomorphic allele, which express
only 30%of the wild-type levels of MDM2,
showed a delay in the development of
intestinal tumors arising from a mutantptember 14, 2010 ª2010 Elsevier Inc. 201
Figure 1. MDM2SNP309G Suppresses p53
Pathway Activation and Accelerates Tumor
Formation
The transcription factor Sp1 has increased affinity
for MDM2SNP309G, resulting in elevated MDM2
expression; the consequent inhibition of the p53
pathway impairs tumor suppression and chemo-
sensitivity (denoted by the blue arrows). Potential
therapeutic strategies for patients with the
MDM2SNP309G allele include treatment with mithra-
mycin A, nutlin, and MI-219 (shown in red).
Cancer Cell
Previewsallele of the adenomatous polyposis coli
gene (Mendrysa et al., 2006). This exqui-
site sensitivity of the p53 pathway to
small changes in protein levels has impor-
tant implications for the development
of cancer therapeutic strategies, where
a common approach is to activate p53
in order to induce tumor clearance.
Post and colleagues showed that
MDM2SNP309G reduces p53-dependent
apoptosis after low-dose irradiation. Simi-
larly, this allele reduces the sensitivity of
cells to chemotherapeutic drugs (Vazquez
et al., 2008). Therefore, by suppressing
p53 activation, MDM2SNP309G may nega-
tively affect the ability of a tumor to202 Cancer Cell 18, September 14, 2010 ª20respond to radio- and/or chemotherapy
(Figure 1).
This knowledge may contribute to the
optimization of cancer treatment regi-
mens according to a patient’s genotype.
Small molecules such as nutlin and
MI-219 inhibit the interaction between
p53 and MDM2 and are already in phase
I clinical trials (Brown et al., 2009). In
people carrying the MDM2SNP309G allele,
inhibition of increased levels of MDM2
could be a more effective therapeutic
strategy. Alternatively, the Sp1 inhibitor
mithramycin A, which is already in use
as an anticancer drug, could be used
to block MDM2 upregulation in these
patients and may lead to improved
chemotherapeutic response (Bond et al.,
2004) (Figure 1).
In conclusion, current sequencing tech-
nologies allow unprecedented genome
analysis that has great potential to
advance our understanding of patholo-
gies. There is precedence for the role of
SNPs as active contributors to disease
mechanisms, because a SNP in factor V,
known as factor V Leiden, causes a hyper-
coagulability disorder and an increased
risk of thrombosis. Factor V Leiden carries
an amino acid substitution making the
protein resistant to inactivation (Bertina
et al., 1994). Similarly, a SNP at codon
72 of p53 encodes either proline or argi-
nine and affects the ability of p53 to
induce apoptosis, thus affecting chemo-
sensitivity (Vazquez et al., 2008).
However, it is remarkable that a SNP in
noncodingDNAshould have such a signif-
icant effect on tumor formation, the proof
of which has now been definitively
provided by Post and colleagues. Since
data from clinical studies are controver-
sial because of genetic heterogeneity,
environmental factors, and limited cohort10 Elsevier Inc.sizes, this report also illustrates the impor-
tance of genetically engineered mouse
models as tools for mechanistic studies.
It will be important to identify and analyze
similarly functional SNPs. Such informa-
tion not only has both diagnostic and
prognostic value, but will also allow us to
develop novel treatment strategies and
to optimize them for each patient, taking
us one more step toward personalized
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